These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 9491969)

  • 1. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine.
    Fraser AD; Howell P
    J Anal Toxicol; 1998; 22(1):50-4. PubMed ID: 9491969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. False-positive immunoassay results for urine benzodiazepine in patients receiving oxaprozin (Daypro).
    Camara PD; Audette L; Velletri K; Breitenbecher P; Rosner M; Griffiths WC
    Clin Chem; 1995 Jan; 41(1):115-6. PubMed ID: 7813058
    [No Abstract]   [Full Text] [Related]  

  • 3. Development and validation of a high-performance liquid chromatography method for the evaluation of niflumic acid cross-reactivity of two commercial immunoassays for cannabinoids in urine.
    Kovatsi L; Pouliopoulos A; Papadaki A; Samanidou V; Tsoukali H
    J Anal Toxicol; 2010 May; 34(4):229-32. PubMed ID: 20465870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference of oxaprozin with benzodiazepines via enzyme immunoassay technique.
    Matuch-Hite T; Jones P; Moriarity J
    J Anal Toxicol; 1995; 19(2):130. PubMed ID: 7769785
    [No Abstract]   [Full Text] [Related]  

  • 5. Improved cross-reactivity to alpha OH triazolam in the BMC CEDIA DAU urine benzodiazepine assay.
    Fraser AD; Meatherall R
    Ther Drug Monit; 1998 Jun; 20(3):331-4. PubMed ID: 9631932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study.
    Fraser AD; Worth D
    Ther Drug Monit; 2002 Dec; 24(6):746-50. PubMed ID: 12451292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaprozin interference with urinary benzodiazepine immunoassays and noninterference with receptor assay.
    Nishikawa T; Kamijo Y; Ohtani H; Fraser AD
    J Anal Toxicol; 1999; 23(2):125-6. PubMed ID: 10192417
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values.
    Fraser AD; Meatherall R
    J Anal Toxicol; 1996; 20(4):217-23. PubMed ID: 8835658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations of EMIT benzodiazepine immunoassay for monitoring compliance of patients with benzodiazepine therapy even after hydrolyzing glucuronide metabolites in urine to increase cross-reactivity: comparison of immunoassay results with LC-MS/MS values.
    Dixon RB; Floyd D; Dasgupta A
    Ther Drug Monit; 2015 Feb; 37(1):137-9. PubMed ID: 25004136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
    Darragh A; Snyder ML; Ptolemy AS; Melanson S
    Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The online screening technique for urinary benzodiazepines: comparison with EMIT, FPIA, and GC-MS.
    Beck O; Lin Z; Brodin K; Borg S; Hjemdahl P
    J Anal Toxicol; 1997; 21(7):554-7. PubMed ID: 9399125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of EMIT II, CEDIA, and DPC RIA assays for the detection of lysergic acid diethylamide in forensic urine samples.
    Wiegand RF; Klette KL; Stout PR; Gehlhausen JM
    J Anal Toxicol; 2002 Oct; 26(7):519-23. PubMed ID: 12423010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved screening for benzodiazepine metabolites in urine using the Triage Panel for Drugs of Abuse.
    Koch TR; Raglin RL; Kirk S; Bruni JF
    J Anal Toxicol; 1994; 18(3):168-72. PubMed ID: 7914948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC.
    Fraser AD; Isner AF; Bryan W
    J Anal Toxicol; 1993; 17(7):427-31. PubMed ID: 8309217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
    Pettersson Bergstrand M; Helander A; Hansson T; Beck O
    Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New fluorescence polarization immunoassays for analysis of barbiturates and benzodiazepines in serum and urine: performance characteristics.
    Schwenzer KS; Pearlman R; Tsilimidos M; Salamone SJ; Cannon RC; Wong SH; Gock SB; Jentzen JJ
    J Anal Toxicol; 2000; 24(8):726-32. PubMed ID: 11110029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved CEDIA benzodiazepine assay eliminates sertraline crossreactivity.
    Fitzgerald RL; Herold DA
    J Anal Toxicol; 1997; 21(1):32-5. PubMed ID: 9013289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEDIA dau Benzodiazepine screening assay: a reformulation.
    Meatherall RC; Fraser AD
    J Anal Toxicol; 1998; 22(4):270-3. PubMed ID: 9681328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS.
    Puzyrenko A; Wang D; Schneider R; Wallace G; Schreiber S; Brandt K; Gunsolus IL
    J Anal Toxicol; 2022 Aug; 46(7):712-718. PubMed ID: 34557900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzodiazepine screening using EMIT II and TDx: urine hydrolysis pretreatment required.
    Meatherall R
    J Anal Toxicol; 1994; 18(7):385-90. PubMed ID: 7861751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.